Northwest Biotherapeutics (NWBO) Consolidated Net Income: 2010-2025
Historic Consolidated Net Income for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$16.9 million.
- Northwest Biotherapeutics' Consolidated Net Income fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' Consolidated Net Income stood at -$16.9 million, which was down 2.02% from -$16.6 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Consolidated Net Income registered a high of -$11.7 million during Q3 2021, and its lowest value of -$22.5 million during Q2 2022.
- Its 3-year average for Consolidated Net Income is -$17.0 million, with a median of -$16.9 million in 2024.
- The largest annual percentage gain for Northwest Biotherapeutics' Consolidated Net Income in the last 5 years was 78.18% (2021), contrasted with its biggest fall of 148.49% (2021).
- Over the past 5 years, Northwest Biotherapeutics' Consolidated Net Income (Quarterly) stood at -$11.8 million in 2021, then tumbled by 64.00% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then declined by 28.09% to -$21.0 million in 2024, then fell by 0.36% to -$16.9 million in 2025.
- Its Consolidated Net Income stands at -$16.9 million for Q3 2025, versus -$16.6 million for Q2 2025 and -$18.9 million for Q1 2025.